Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug

Main Article Content

James Del Rosso
JDR Dermatology Research/Thomas Dermatology, Las Vegas, NV, USA

Leon Kircik
Mount Sinai

Linda Stein Gold
Henry Ford Health System, Detroit, MI, USA

Hilary Baldwin
The Acne Treatment & Research Center

Jonathan Weiss
Georgia Dermatology Partners

David Pariser
Eastern Virginia Medical School

Valerie Callender
Callender Dermatology and Cosmetic Center

Edward Lain
Austin Center for Clinical Research

Michael Gold
Gold Skin Care Center

Kenneth Beer
University of Miami Miller School of Medicine

Zoe Draelos
Dermatology Consulting Services, PLLC High Point, NC

Neil Sadick
Sadick Dermatology, New York, NY

; Radhakrishnan Pillai
Bausch Health US, LLC, Bridgewater, NJ

Varsha Bhatt
Bausch Health US, LLC, Bridgewater, NJ

Emil Tanghetti
Center for Dermatology and Laser Surgery, Sacramento, CA

Keywords

acne

Abstract

N/A

References

1. Del Rosso JQ, Schmidt NF. Cutis. 2010;85(1):15–24.

2. Zaenglein AL, et al. J Am Acad Dermatol. 2016;74(5):945–73.

3. Stein Gold, L, et al. Am J Clin Dermatol. 2021. doi: 10.1007/s40257-021-00650-3.

Article Sidebar

Poster PDF
Published
Mar 4, 2022
DOI https://doi.org/10.25251/skin.6.supp.17

Article Details

How to Cite
Del Rosso, J., Kircik, L. ., Stein Gold, L., Baldwin, H. ., Weiss, J. ., Pariser, D., Callender, V. ., Lain, E. ., Gold, M., Beer, K. ., Draelos, Z., Sadick, N., Pillai, ; R., Bhatt, V., & Tanghetti, E. (2022). Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug. SKIN The Journal of Cutaneous Medicine, 6(2), s17. https://doi.org/10.25251/skin.6.supp.17
Issue
Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Section
Acne & Rosacea
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>